Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary pulmonary hypertension

S P Gaine1, L J Rubin

  • 1Division of Pulmonary and Critical Care Medicine, University of Maryland School of Medicine, Baltimore 21201, USA.

Lancet (London, England)
|September 5, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Case 1: chronic thromboembolic pulmonary hypertension (CTEPH).

Irish medical journal·2013
Same author

Case 2: Silicosis.

Irish medical journal·2013
Same author

A decade of achievement in pulmonary hypertension.

European respiratory review : an official journal of the European Respiratory Society·2011
Same author

Stabilization of meat lipids with nitrite-free curing mixtures.

Meat science·2011
Same author

Cardiovascular effects of pulmonary hypertension.

Trends in cardiovascular medicine·2011
Same author

Pulmonary arterial hypertension and the state of limbo.

European respiratory review : an official journal of the European Respiratory Society·2010

Primary pulmonary hypertension (PPH) is a rare, progressive disease affecting young women. Advances in diagnosis and treatment over 20 years have improved outcomes for patients with this severe condition.

Area of Science:

  • Cardiology
  • Pulmonology
  • Vascular Biology

Background:

  • Primary pulmonary hypertension (PPH) is a severe, progressive disease leading to right-heart failure.
  • It predominantly affects young to middle-aged women with a poor prognosis of 2-3 years survival.
  • The exact cause is unknown, but genetic factors and endothelial-smooth muscle cell interactions are implicated.

Purpose of the Study:

  • To review advancements in the diagnosis and treatment of PPH over the last two decades.
  • To highlight current understanding of PPH pathogenesis.
  • To discuss diagnostic strategies and therapeutic options.

Main Methods:

  • Diagnostic evaluation involves excluding secondary causes and hemodynamic assessment via catheterization.
  • Vasoreactivity testing during acute drug challenge identifies potential responders to calcium-channel blockers.

Related Experiment Videos

  • Review of therapeutic interventions including medical therapy and transplantation.

    • Main Results:

    • Approximately 30% of PPH patients show vasoreactivity, predicting positive response to calcium-channel blockers.
    • Intravenous epoprostenol (prostacyclin) improves outcomes in severe PPH patients unresponsive to acute testing.
    • Thoracic transplantation is a last resort for medically refractory cases.

    Conclusions:

    • Significant progress has been made in PPH diagnosis and management over the past 20 years.
    • Early diagnosis and appropriate treatment, including vasodilators and prostacyclin, can improve PPH patient outcomes.
    • Further research into PPH etiology and pathogenesis is crucial for developing novel therapies.